TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kingworld Medicines Group Ltd. ( (HK:1110) ) just unveiled an announcement.
Kingworld Medicines Group Ltd. announced an expected significant decrease in profits for the first half of 2025, with a projected drop of 70% to 75% compared to the same period in 2024. This decline is attributed mainly to a reduction in gross profit from the distribution of imported pharmaceutical and healthcare products in China, driven by a slowdown in market demand. Despite a slight increase in profits from its subsidiary Dong Di Xin, the company anticipates a loss of approximately RMB4.5 million for the period, compared to a profit of RMB30.7 million in the previous year.
The most recent analyst rating on (HK:1110) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Kingworld Medicines Group Ltd. stock, see the HK:1110 Stock Forecast page.
More about Kingworld Medicines Group Ltd.
Kingworld Medicines Group Ltd. operates in the pharmaceutical and healthcare industry, focusing on the distribution of imported branded pharmaceutical and healthcare products in China. The company also has a non-wholly owned subsidiary, Shenzhen Dong Di Xin Technology Company Limited, which manufactures medical devices such as infrared thermometers and rehabilitation equipment.
Average Trading Volume: 1,216,306
Technical Sentiment Signal: Buy
Current Market Cap: HK$376M
For an in-depth examination of 1110 stock, go to TipRanks’ Overview page.